Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia. However, GVHD rate was still high after haploidentical HSCT. It was found in our previous study that CD4/CD8\>=1.16、CD56bright NK\>1.9×106/kg in the graft was associated with higher risk of developing acute Graft-versus-host Disease (GVHD). The study hypothesis: Risk stratification-directed low-dose glucocorticoid prophylaxis for acute GVHD after unmanipulated haploidentical blood and marrow transplantation can reduce the incidence of acute GVHD
patients undergone haploidentical HSCT following day 5 post transplant were randomized to treated group(low-dose glucocorticoid) and controlled group(no intervention).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
145
patients receive low-dose glucocorticoid from day 5 post transplant
Peking University People's Hospital，Institute of Hematology
Beijing, China
Peking University People's Hospital
Beijing, China
incidence of acute graft-versus-host disease
number of participants with acute graft-versus-host disease at 100 days
Time frame: paticipants will be followed for the duration of hospital stay,an expected average of 100 days
incidence of infection
number of participants with infection (including bacterium,EB virus, cytomegalovirus and fungus ) at 100 days
Time frame: participants will be followed for the duration of hospital stay,an expected average of 100 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.